Many new parents are apprehensive about donating their baby’s cord blood stem cells because of inadequate knowledge about the collection, processing, and storage of umbilical cord blood. The process of collecting and storing cold blood cells must be explained in a comprehensive manner so that expecting parents may be fearless about the collection process and any unknown risks surrounding the process. No risk or pain for the child or mother is associated with cord blood collection methods during pre or post operative procedures. To retrieve the diverse life saving opportunities from it, a once disposable umbilical cord is now worthy of being stored with all the miraculous therapeutic benefits of cord blood cells.

The storage of cord blood involves two steps. These are the collection process and the actual processing of the umbilical cord blood.

The blood cell collection is the first step. According to the period of collection, the collection method can vary. There are two potential methods, both of which are equally safe.

The first method involves collecting blood when the doctor or the midwife is waiting for the placenta to be delivered or the period of 5 to 10 minutes before the delivery of the placenta. This is method that takes place before the placenta is delivers is referred to as In utero collection.

In a similar procedure, the second method involves draining the cord blood into a bag after placing the placenta in a sterile supporting structure. The umbilical cord is clamped and cut off and drained by syringe. This method is called Ex utero collection and only differs significantly from In utero in the time of collection.

Both of these methods are safe for cesarean and vaginal deliveries, so women in either case can consider donating cord blood stem cells. However, doctors or the cord blood bank may decide to abandon the cord blood collection protocol if complications arise during the final stages of the pregnancy. Per regulations, some of the mother’s blood gets collected to detect ant infectious diseases if present; this is done at the same time the cord blood is harvested from the umbilical vein. To collect adequate cells for transplantation, approximately 40ml to 150ml of cord blood must be drained from the umbilical cord. As much blood as possible is harvested by specialists in all cases. Even if the quantity is limited, the blood is still preserved for possible scientific research or future stem cell expansion, both of which are performed with the individual’s consent only. The parents choose a cord blood storage facility in advance of the birth or delivery, and after collection the blood is forwarded to the respective cord blood bank. The blood is tested for infectious diseases or typecasting of tissues once it reaches the banking facility.

Within 36 to 48 hours of collection, the samples are transferred from the cord blood bank to a lab. The mother’s blood is tested for diseases like CMV, HIV, syphilis, Malaria, and hepatitis. The testing labs which are CLIA certified are also registered with the FDA. The cord blood, which can already be used autologously, is deemed eligible for transplant use on family members after processing and infectious disease status is determined to be clean. One detail that deserved mention is that to ensure that the mother is eligible for cord blood donation, she usually has to undergo a special test during cord blood registry prior to the donation. The parents can prepare themselves for treatment if necessary after they receive the results.

While some processing methods keep the red blood cells, other types of processing deplete the cord blood of red blood cells. A cryopreservant is added to the now processed cord blood to ensure the unit of cord blood will survive the cryogenic process; this is the next step towards preservation. A liquid nitrogen tank is used for cord blood storage which brings the temperature of the cord blood unit down to -90 degrees Celsius. The cord blood unit is stored so that part of the blood can be reserved for stem cell expansion while the other part can be used immediately if required, thus, the bag is divided into two compartments for this reason.

In the case of private banking, the rights for future transplantation are given to the child’s parents or guardians. The child gains authority over his or her cord blood cells once they reach legal age. Public banks, as the name implies, utilize donated cord blood so the family gives up control over their cord blood upon donation. Cord blood banks assure donors that complete confidentiality will be kept at all times, which eases those concerned with privacy issues. Recipients of cord blood will never know the donor’s identity, and if the recipient is a stranger, the privacy measures are even more strict.

You family could be saved from many dreaded diseases with umbilical cord blood. Many killer diseases can be treated using umbilical cord blood since it is composed of an abundance of stem cells. Even if cost is an issue, the blood can be donated to a public cord blood bank so that at the very least, others can benefit from its life-saving potential.

Capable of seeking out tumors and destroying theme like tiny homing missiles, mesenchymal stem cells derived from adipose, or fat tissue, have been engineered by researchers in Slovakia. The modified cells have been called, “suicide genes”. In a journal of the American Association for Cancer Research, the July 1 issue of Cancer Research, the Slovakian scientists concluded that this gene therapy approach was a novel way to attack small tumor metastases that evade current detection techniques and treatments.

“These fat-derived stem cells could be exploited for personalized cell-based therapeutics,” said the study’s lead investigator, Cestmir Altaner, Ph.D., D.Sc., an associate professor in the Cancer Research Institute of the Slovak Academy of Sciences in Bratislava. “Nearly everyone has some fat tissue they can spare, and this tissue could be a source of cells for cancer treatment that can be adapted into specific vehicles for drug transport.”

By renewing injured cells, mesenchymal stem cells help repair damaged tissue and organs. Solid tumors are also made up of a mix of cancer cells and normal cells, some of which are mesenchymal stem cells. The cells may be able to find both small metastases as well as primary tumors because mesenchymal stem cells are believed to be able to “see” a tumor as a damaged organ and migrate to it. For this reason, researchers believe that the cells can be used as a vehicle for treatment.

The standard therapy for colon cancer is to use a chemotherapy agent called 5-fluorouracil (5-FU), which can produce toxic side effects in normal cells. With this in mind, the researchers worked to find a less toxic way to treat colon cancer with the stem cells they extracted from human fat tissue. The gene cytosine deaminase was inserted into the cell using a retrovirus vector after the mesenchymal stem cells were expanded in a laboratory. A lethal bystander effect can be produced by the gene, which can convert a less toxic drug, 5-fluorocytosine (5-FC), to 5-FU inside the stem cells, and the chemotherapy can then seep out into the tumor.

The researchers injected the engineered mesenchymal stem cells, then 5-FC, into mice with inhibited immune systems who were engrafted with human colon cancer. None of the mice exhibited any signs of toxic side effects while up to a 68.5 percent inhibition of tumor growth was observed in the animals.

However, none of the animals remained tumor-free. “The procedure was quite effective even though we applied the stem cells just once. Obviously, repeated treatment will increase the efficacy, as would using this strategy in combination with other treatments,” Altaner said.

The yield of normal mesenchymal stem cells from fat tissue is far greater than when the cells are derived from other sources such as bone marrow.

Altaner said that the, “removal of fat tissue during surgery to remove a tumor would be simple.”

Mesenchymal stem cells can also be gathered and isolated through liposuction, and the cells frozen in liquid nitrogen for future therapeutic use. Both processes would be easier than taking bone marrow from a patient, Altaner said.

The Slovakian national cancer genomics program supported the study and the League Against Cancer along with the Slovak Academy of Sciences provided grants for funding.

Those suffering from stress incontinence could be presented with a new method of treatment soon involving none other than stem cell technology.

Women make up the predominance of incontinence sufferers, with an estimated 13 million Americans suffering from some form of the condition. The cause of this condition varies with stroke, obesity, urinary tract infections, abnormal urinary tract, medicine, enlarged prostate, bladder infections, constipation, nerve damage, or surgery, all being possible causes of the condition. The condition can afflict persons of any age but a common in the elderly.

Whenever urethral pressure exceeds bladder pressure inside the body, the physical state is called continence. Reducing the possibility of incontinence or leakage, this unequal pressure balance keeps urine safely confined within the bladder.

Incontinence can be broken down into four major types. One common type occurs when patients still have sufficient control over their bladders to make it to the bathroom on time, but the urgency to urinate is frequent. Stress incontinence manifests when bladder muscles are initially weak to begin with and lifting a heavy object places undue pressure on the bladder muscles. Stress incontinence can even be caused by fits of coughing, sneezing, or laughing, that exerts pressure on the bladder muscles. A combination of urge incontinence and stress incontinence is referred to as mixed incontinence. Finally, a blockage in the bladder that makes it impossible to release urine in moderation, nerve damage, or weak muscle contractions, leads to overflow incontinence.

Stem cells may one day help men who become incontinent after prostate surgery. Researchers at the University of Pittsburgh and the University of Calgary are studying the procedure at this time. Technicians isolate stem cells from muscle tissue that has been removed from a patient’s leg by doctors. With the hope they will strengthen pre-existing muscles in such a way that urges can be controlled, the stem cells are later injected into the muscles that surround the urethra. The researchers have demonstrated that 60 percent of patients experience improvement within the first year. The transplant itself, only takes five minutes.

Traditional treatments have ranged from targeted exercise to surgical intervention.

Oftentimes, they are difficult, time-consuming, and difficult to do without a professional, but Kegel exercises can be utilized to strengthen the sphincter muscles and pelvic floor.

To strengthen the pelvic floor muscles responsible for bladder control, brief electrical impulses can be administered as a form of electrical stimulation.

Medication can also be prescribed to aid those with incontinence. Medications that prevent leakage by tightening the muscles in the bladder and urethra or that inhibit contractions of an overactive bladder may be prescribed. Estrogen has also been known to precipitate normal functioning of muscles responsible for continence.

A form of treatment called vaginal cone therapy is sometimes used by women to strengthen the pelvic floor muscles. The process involves placing plastic cones of increasing weight in the vagina and holding them there for 15 to twenty minutes, twice a day.

The bladder can be repositioned surgically in women where it has dropped down towards the vagina. Doctors hoist the bladder back up by securing it to bone, ligament, or muscle.

But with 85 percent effectiveness, the most preferred method treatment for stress incontinence among females requires surgery where the urethra is supported and strengthened by a mesh material that is inserted below the area.

Stem cells could resolve all of the current methods of treatment with a minimally invasive procedure. Surgery could be avoided altogether and equal or greater results may soon be attained with stem cell treatment.

Patients with immunoglobulin-light chain (AL) Amyloidosis who did not respond to initial treatment with high-dose chemotherapy and blood stem cell transplantation can be helped by utilizing tandem cycles of the treatment. The finding, which was published in the June 25th issue of Bone Marrow Transplantation on-line, was made by researchers from the Stem Cell Transplant Program and the Amyloid Treatment and Research Program at Boston University Medical Center (BUMC).

Leading to organ failure and death, when clonal plasma cells in bone marrow produce proteins that misfold and deposit in tissues, the condition is called AL amyloidosis. Researchers believe the disease is highly under-diagnosed, despite the fact that in the United States between 1,200 and 3,200 new cases are reported each year.

17 patients who had not achieved a complete remission from their initial treatment out of the initial 62 enrolled in the trial received a second course of high-dose chemotherapy and blood stem cell transplantation. This was the process used to determine whether or not a second course could be beneficial. After receiving a second course of treatment, a complete hematologic remission of their amyloidosis was achieved by 5 of the 17 patients, equating to a 31 percent success rate.

This approach appears to be associated with an improvement in overall survival as it increases the proportion of patients who ultimately achieve a complete response stated lead researcher, Vaishali Sanchorawala, MD, who is the clinical director of the Stem Cell Transplant Program, section of hematology/oncology at BUMC and associate professor of medicine at Boston University School of Medicine.

New treatments to amplify the success of cord blood and bone marrow transplants in humans could be developed thanks to a new discovery related to zebrafish. Blood-forming stem cell production is enhanced due to a natural chemical that is produced by the fish.

The finding was published in the June 21, 2007 issue of the journal Nature. At the Children’s Hospital in Boston, Leonard Zon, a Howard Hughes Medical Institute researcher, led the team. The lead author of the study was a postdoctoral fellow in Zon’s laboratory named Trisha North.